Azienda Ospedaliera Policlinico "Mater Domini" Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04322344
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Azienda Ospedaliera Policlinico "Mater Domini"

Active Ingredients

Drugs in Phase 3 Trials (2)

COVID-19 convalescent plasma (1 trial)

sodium aescinate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 3)

Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2